Please assess the completion status of the following clinical trial:

Trial Title: Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients \> 1 months post-transplant,~* No history of chronic diarrhea pre-transplant,~* \>3 watery/soft stools after transplant on at least 4 days in the week without anti-diarrheal for at least 2 weeks or using anti-diarrheals for at least 4 days in the week \> 2 weeks~* Subjects on at least 180mg twice a day of mycophenolate-sodium or 250 mg twice a day of cellcept~Exclusion Criteria:~* Diagnosis of any known colonic diseases (i.e. Crohn's disease, ulcerative colitis, ischemic colitis, Celiac disease), partial colonic resection, small bowel resection, history of cholecystectomy, Irritable Bowel Syndrome, fecal Incontinence, Bacterial overgrowth, infectious diarrhea (c difficle, cryptospora, giardia, isospora, Human Immunodeficiency Virus), Cytomegalovirus colitis~* Subjects with recent acute rejection treated with high dose steroids~* Subjects taking Boswellia serrata extract, over-the-counter herbs, cholestyramine, nonsteroidal salicylates (other than daily ASA)~* Subjects with active malignancy, liver cirrhosis, active peptic ulcer disease, known intolerance or resistance to budesonide, pregnancy, breast-feeding, mental retardation~* Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Entocort EC (Type: EXPERIMENTAL): Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will take 6mg matching placebo pill daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).